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Abstract: Plasmepsin group of enzymes are key enzymes in the life
cycle of malarial parasites. As inhibition of plasmepsins leads to the
parasite’s death, these enzymes can be utilized as potential drug
targets. Although many drugs are available, it has been observed
that Plasmodium falciparum, the species that causes most of the
malarial infections and subsequent death, has developed
resistance against most of the drugs. Based on the cleavage sites of
hemglobin, the substrate for plasmepsins, we have designed two
compounds (p-nitrobenzoyl-leucine-b-alanine and p-nitrobenzoyl-
leucine-isonipecotic acid), synthesized them, solved their crystal
structures and studied their inhibitory effect using experimental
and theoretical (docking) methods. In this paper, we discuss the
synthesis, crystal structures and inhibitory nature of these two
compounds which have a potential to inhibit plasmepsins.
Abbreviations: DCC, dicylohexyl carbodiamide; HAP, histo-asparstic
protease; Hb, hemoglobin; HOBt, 1-hydroxybenzotrizole.
Introduction
Every year, billions of people are infected with malaria and
close to 3 million people die because of the disease (1).
Malaria is caused by four major species, Plasmodium fal-
ciparum, P. vivax, P. malariae, and P. ovale. Among these
four major species, P. falciparum alone accounts for more
than 95% of the malaria cases (2). Although many anti-
malarial drugs are available, both P. falciparum and P. vivax
have developed resistance for almost all the available drugs
(3,4). Therefore, to find newer antimalarial agents is indeed
the need of the hour.
The asexual development of the malarial parasite takes
place in human erythrocyte or the red blood cell (RBC).
During this stage, the parasite utilizes hemoglobin (Hb) of
RBC as the only source of food. Three different classes of
enzymes present in the food vacuole of the malarial
parasite – falcipain (cysteine protease) (5), falcilysin (met-
alloprotease) (6) and plasmepsins (aspartic proteases) (7) –
are responsible for the digestion of Hb. Of the three dif-
ferent classes of enzymes involved in the digestion of Hb,
plasmepsins are known to be the key enzymes as they
initiate the catalytic breakdown of Hb. Hence, these en-
zymes can be probed as potential drug targets. Three
aspartic proteases (plasmepsin I, II and IV) and one histo-
aspartic protease (HAP) are involved in Hb degradation
(8,9). Plasmepsins I and II are involved in the first phase of
Hb degradation, while plasmepsin IV and HAP either
partially digest Hb or act on the degradation products of
the first phase to cleave them into smaller peptides. Re-
cent genome data of P. falciparum revealed the presence of
six more plasmepsins (plasmepsins V to X) in the parasite.
These enzymes share much less similarity among them-
selves and with the other four aspartic proteases and their
functions are not yet known.
Since the identification of plasmepsins in 1994 (10),
numerous attempts have been made to design inhibitors of
plasmepsins with a view to develop them into potent anti-
malarial drugs. A wide variety of them have been designed,
synthesized, checked for activity by enzyme assays as well
as in parasite cultures. They include both peptide-like
(7,11,12) and non-peptidyl (4,13,14) inhibitors. Some of them
were designed based on the substrate structure (Phe33-
Leu34 of Hb) (15) and/or statine residue (16) of the universal
aspartic protease inhibitor, pepstatin. C2 symmetric (17) and
achiral inhibitors (4) were also reported. The determination
of the crystal structure of plasmepsin II in complex with
pepstatin revealed intricate details of the mode of binding
and provided a platform for the structure-based design (18).
Subsequent crystal structures of plasmemsin II with other
inhibitors (13,15) revealed the conformational flexibility of
the binding pocket and an entirely new type of binding (19).
Modeling/docking, molecular dynamics and interaction
energy calculations were also performed in many studies
(4,17). Some of the compounds could successfully inhibit
the enzyme but failed to stop the parasite growth in cell
culture (4,7,18) probably because of their size that prevents
the access to the food vacuole of the parasite where the Hb
degradation occurs. The strategy for a viable drug is to find a
relatively small, cost-effective and highly specific inhibitor.
Although many inhibitors targeting the plasmepsin group of
enzymes are available, none of them are in use as drugs for
the treatment of malaria today. We have designed and
synthesized two small compounds (Fig. 1) based on the Hb
cleavage sites of plasmepsins and also incorporated a b-
amino acid in one of them and the isonipecotic acid group in
the other as alternate strategies for inhibitor design with a
view to test the feasibility of developing them as effective
antimalarials. To study the interaction of these compounds
with plasmepsin I, we have crystallized both the com-
pounds, determined their crystal structures and performed
docking studies using the crystal structures, the results of
which are presented in this paper.
Experimental Procedures
Synthesis of compounds
The compounds were synthesized by the stepwise solution-
phase method. Dicyclo hexylcarbodiamide (DCC) was used
for the formation of the peptide bond.
p-(NO2)-Ba-(L),(D)-Leu-b-Ala-OMe (Asp-12 & Asp-13)
p-(NO2)-Ba-(l)-Leu-OH or p-(NO2)-Ba-(d)-Leu-OH (0.9 g,
3.21 mm) was dissolved in 10 mL of ethyl acetate and
cooled to 0 C in an ice bath. H-b-Ala-OMe, isolated from
Figure 1. Chemical structures of (A) p-nitrobenzoyl-leucine-b-alanine
(Asp-12) and (B) p-nitrobenzoyl-leucine-isonipecotic acid (Asp-20).
 
0.7 g (6.42 mm, 2 eq.) of hydrochloride was neutralized,
followed by extraction with ethyl acetate and concentration
to approximately 5 mL. It was then added to p-(NO2)-Ba-
Leu-OH under stirring while maintaining the temperature
at 0 C, followed immediately by the addition of DCC/1-
hydroxybenzotrizole (HOBt) of 0.70 g (3.21 mm)/0.43 g
(3.21 mm). The reaction mixture was allowed to reach room
temperature and stirred for 3–4 h. The precipitated dic-
yclohexylurea was filtered off. The organic layer was wa-
shed successively with 2 n HCl (3 · 50 mL), brine
(3 · 50 mL), 1 m sodium carbonate (3 · 50 mL) and brine
(3 · 50 mL). This layer was then dried over anhydrous so-
dium sulfate and was evaporated to yield a white solid. The
crude peptide was recrystallized from petroleum ether to
obtain Asp-12/Asp-13. The sample was purified over silica
gel using chloroform–methanol as an elutant to yield 0.96 g
(2.63 mm, 82.10%) of Asp-12/Asp-13.
p-(NO2)-Ba-(L),(D)-Leu-Ina-OMe (Asp-20 & Asp-21)
p-(NO2)-Ba-(l)-Leu-OH or p-(NO2)-Ba-(d)-Leu-OH (0.28 g,
1.0 mm) was dissolved in 5 mL of ethyl acetate and cooled to
0 C in an ice bath. H-Ina-OMe (Ina-isonipecotic acid), iso-
lated from 0.28 g (2.0 mm, 2 eq.) of hydrochloride was
neutralized, followed by extraction with ethyl acetate, and
concentration to approximately 5 mL. Itwas then added to p-
(NO2)-Ba-Leu-OH under stirring while maintaining the
temperature at 0 C, followed immediately by the addition of
DCC/HOBt of 0.21 g (1.0 mm)/0.14 g (1.0 mm). The reaction
mixture was allowed to reach room temperature and stirred
for 3–4 h. The precipitated dicyclohexylurea was filtered off.
The organic layer was washed successively with 2 n HCl
(3 · 50 mL), brine (3 · 50 mL), 1 m sodium carbonate
(3 · 50 mL) and brine (3 · 50 mL). This layer was then dried
over anhydrous sodium sulfate and was evaporated to yield a
white solid. The crude peptide was recrystalized from pet-
roleum ether to obtain Asp-20/Asp-21. The sample was
purified over silica gel using chloroform–methanol as an
elutant to yield 0.35 g (0.86 mm, 86.30%) of Asp-20/Asp-21.
Characterization
Elemental analysis of the compounds was carried out using
a ThermoFinnigan FLASH EA 1112 CHNS analyser (Ther-
mo Electron Corporation, Waltham, MA, USA) and the
Table 1. Details of crystal data, data collection and refinement
parameters
Asp-12/Asp-13 Asp-20/Asp-21
Empirical formula C17H23N3O6 C20H27N3O6
Crystal size (mm) 0.44 · 0.19 · 0.09 0.2 · 0.17 · 0.1
Crystallizing solvent Acetone Acetone
Crystal system Triclinic Monoclinic
Space group P 1 C 1 2/c 1
Unit cell dimensions
a (A˚) 8.791(3) 17.246(4)
b (A˚) 9.725(3) 12.800(3)
c (A˚) 11.165(4) 19.708(4)
a () 92.231(6) 90
b () 95.723(6) 96.138(5)
c () 98.977(6) 90
Volume (A˚3) 936.7(13) 4325.36(29)
Z 2 8
Mr 365.4 405.5
Density (g/cm3) (cal) 1.3 1.25
F(000) 387.9 1727.7
Radiation (k in A˚) MoKa (0.71073) MoKa (0.71073)
Temperature (C) 20 25
Unique reflections 3913 2278
Observed reflections 3023 1374
Final R (%) 3.63 6.76
Final wR2 (%) 7.56 14.62
Goodness of fit (S) 0.957 1.009
Dqmax (e A˚
)3) 0.120 0.428
Dqmin (e A˚
)3) )0.093 )0.154
Data-to-param ratio 8.2:1 8.5:1
Figure 2. Molecular conformation of (A) Asp-12 & Asp-13 and (B)
Asp-20. The thermal ellipsoids are at 50% probability level.
Table 2. Coordinates and equivalent isotropic thermal parameters (· 103 A˚2) of nonhydrogen atoms (estimated standard deviations are
given in parentheses)
Asp-12
O1 )0.5067 (0.0070) )1.4406 (0.0067) 1.5154 (0.0061) 1060 (30)
O2 0.1822 (0.0071) 0.0081 (0.0063) 0.0504 (0.0058) 1189 (29)
N1 0.0890 (0.0071) )0.4805 (0.0076) 1.1807 (0.0074) 886 (31)
C1 0.7506 (0.0075) 0.2754 (0.0072) 2.3204 (0.0075) 578 (30)
C2 0.6096 (0.0077) )0.1022 (0.0055) 3.5786 (0.0069) 702 (30)
C3 1.2293 (0.0071) 0.6880 (0.0068) 4.6132 (0.0063) 585 (27)
C4 1.9832 (0.0064) 1.7183 (0.0061) 4.2803 (0.0064) 480 (23)
C5 2.1786 (0.0071) 2.0284 (0.0083) 2.9870 (0.0075) 804 (32)
C6 1.5215 (0.0087) 1.2953 (0.0098) 1.9448 (0.0075) 922 (40)
C7 2.7881 (0.0062) 2.4696 (0.0067) 5.3023 (0.0064) 578 (31)
O3 3.5516 (0.0059) 3.3398 (0.0056) 4.9106 (0.0056) 957 (23)
N2 2.6303 (0.0055) 2.2322 (0.0053) 6.5935 (0.0048) 572 (23)
C8 3.4035 (0.0064) 2.9187 (0.0063) 7.6185 (0.0064) 627 (27)
C9 2.6750 (0.0068) 3.0248 (0.0085) 8.8924 (0.0074) 797 (33)
C10 3.4081 (0.0069) 3.7288 (0.0064) 10.0557 (0.0058) 600 (26)
C11 2.5807 (0.0102) 3.5924 (0.0098) 11.3526 (0.0083) 1007 (39)
C12 3.7013 (0.0093) 5.2028 (0.0074) 9.8164 (0.0087) 1000 (40)
C13 4.7541 (0.0059) 2.2119 (0.0063) 7.7960 (0.0054) 373 (23)
O4 4.8284 (0.0040) 1.0535 (0.0044) 8.1494 (0.0040) 541 (18)
N3 5.8411 (0.0047) 2.9984 (0.0050) 7.5924 (0.0049) 467 (20)
C14 7.2394 (0.0058) 2.4862 (0.0066) 7.7391 (0.0063) 533 (22)
C15 7.5627 (0.0063) 2.4046 (0.0059) 9.2402 (0.0063) 452 (25)
C16 7.5353 (0.0068) 3.7258 (0.0072) 9.9451 (0.0073) 561 (30)
O5 7.6104 (0.0057) 4.7796 (0.0050) 9.3857 (0.0053) 795 (23)
O6 7.4462 (0.0053) 3.6019 (0.0047) 11.2404 (0.0050) 744 (21)
C17 7.4488 (0.0113) 4.8222 (0.0094) 12.0421 (0.0094) 1386 (52)
Asp-13
O7 5.6127 (0.0067) 1.1787 (0.0074) 15.8850 (0.0064) 1248 (31)
O8 6.3195 (0.0065) 2.5602 (0.0061) 14.4591 (0.0063) 1104 (28)
N4 5.6861 (0.0069) 1.5165 (0.0075) 14.7451 (0.0060) 731 (30)
C18 5.0287 (0.0072) 0.7412 (0.0073) 13.7249 (0.0068) 567 (29)
C19 5.1982 (0.0064) 1.1325 (0.0070) 12.4067 (0.0068) 730 (31)
C20 4.5564 (0.0080) 0.4735 (0.0071) 11.4689 (0.0071) 725 (32)
C21 3.7138 (0.0066) )0.6545 (0.0070) 11.7126 (0.0068) 570 (29)
C22 3.6911 (0.0096) )1.0572 (0.0095) 13.0638 (0.0083) 1028 (39)
C23 4.2925 (0.0099) )0.3978 (0.0094) 14.0296 (0.0089) 946 (37)
C24 2.9622 (0.0077) )1.4539 (0.0061) 10.7227 (0.0070) 647 (32)
O9 2.1712 (0.0060) )2.3257 (0.0063) 11.0692 (0.0051) 1044 (27)
N5 3.1430 (0.0049) )1.1632 (0.0046) 9.4130 (0.0053) 501 (21)
C25 2.3376 (0.0059) )1.8784 (0.0053) 8.4144 (0.0053) 430 (22)
C26 3.1129 (0.0063) )1.9559 (0.0059) 7.0886 (0.0063) 507 (25)
C27 2.3997 (0.0069) )2.6978 (0.0066) 5.9524 (0.0073) 627 (31)
C28 3.2062 (0.0097) )2.5632 (0.0092) 4.6998 (0.0083) 991 (35)
C29 2.1428 (0.0086) )4.1365 (0.0071) 6.2802 (0.0072) 849 (32)
C30 1.0169 (0.0071) )1.1951 (0.0068) 8.2192 (0.0060) 500 (27)
O10 0.9483 (0.0040) 0.0211 (0.0040) 7.8431 (0.0042) 549 (18)
composition was confirmed (Asp-12: C17H23N3O6 and
Asp-20: C20 H27N3O6). Mass of the compounds was deter-
mined by electronspray mass spectrometry (Asp-12: Mcal ¼
365.4, Mobs ¼ 366.2; Asp-20: Mcal ¼ 405.5, Mobs ¼ 404.3).
The purity of the compounds was confirmed by thin-layer
chromatography (TLC) by spotting them on silica gel 60
plates and developing with the following solvent systems: (i)
chloroform:methanol:acetic acid 9:3:1 and (2) hexane:ethyl
acetate 13:7. High-pressure liquid chromatography was
performed by injecting the samples into a C18 reverse-phase
column (4.6 · 150 mm, 5 lm) and eluting with acetonitrile.
Single peaks (retention time 4.62 min for Asp-12 and
3.49 min for Asp-20) were detectedwith absorbance detector
at 230 nm). Themelting pointswere found to be between 118
and 119 C for both the compounds.
The 1H-nuclear magnetic resonance (NMR) spectra were
recorded in CDCl3 and the
13C-NMR spectra were recorded
in dimethyl sulfoxide (DMSO)-d6 with 400 MHz Bruker
Table 2. Continued
N6 )0.0526 (0.0054) )1.8982 (0.0047) 8.4361 (0.0050) 476 (21)
C31 )1.3601 (0.0065) )1.4275 (0.0055) 8.2055 (0.0061) 463 (23)
C32 )1.7958 (0.0074) )1.3366 (0.0066) 6.7547 (0.0066) 569 (29)
C33 )1.7847 (0.0060) )2.6770 (0.0070) 6.0996 (0.0067) 493 (26)
O11 )1.8240 (0.0056) )3.7593 (0.0049) 6.6511 (0.0053) 770 (24)
O12 )1.7382 (0.0051) )2.5364 (0.0046) 4.7605 (0.0049) 725 (22)
C34 )1.7024 (0.0078) )3.7538 (0.0074) 3.9848 (0.0071) 749 (32)
Asp-20
O4 )0.7270 (0.0031) 0.1389 (0.0038) 11.8792 (0.0031) 559 (14)
O3 )3.1508 (0.0031) )2.2724 (0.0035) 11.8319 (0.0035) 580 (14)
N2 )1.8218 (0.0043) )1.7139 (0.0042) 10.1143 (0.0049) 494 (17)
N3 )0.1124 (0.0040) )1.5201 (0.0045) 13.2575 (0.0043) 555 (17)
C4 )4.2251 (0.0050) )1.5985 (0.0045) 9.8276 (0.0055) 462 (20)
C1 )6.5243 (0.0057) )1.2527 (0.0049) 8.3882 (0.0069) 582 (25)
O2 )8.8317 (0.0049) )1.0625 (0.0046) 8.2334 (0.0055) 1070 (23)
C7 )3.0131 (0.0052) )1.8811 (0.0049) 10.6790 (0.0059) 482 (22)
C9 0.6009 (0.0047) )1.8893 (0.0050) 10.0212 (0.0049) 556 (23)
C8 )0.6291 (0.0045) )2.0125 (0.0049) 10.9002 (0.0047) 483 (22)
C2 )5.3693 (0.0061) )1.4853 (0.0052) 7.7225 (0.0055) 621 (22)
N1 )7.7766 (0.0063) )1.0992 (0.0054) 7.5989 (0.0073) 851 (29)
C5 )5.4213 (0.0057) )1.3463 (0.0051) 10.4597 (0.0055) 621 (24)
C13 )0.5101 (0.0045) )1.0645 (0.0061) 12.0655 (0.0053) 448 (21)
C3 )4.2171 (0.0052) )1.6636 (0.0049) 8.4473 (0.0055) 578 (23)
C6 )6.5868 (0.0056) )1.1759 (0.0054) 9.7523 (0.0067) 678 (26)
C18 0.2201 (0.0054) )0.5858 (0.0056) 14.3283 (0.0051) 661 (24)
C16 2.1215 (0.0050) )2.0873 (0.0063) 14.9781 (0.0053) 670 (25)
C17 1.6925 (0.0056) )0.6754 (0.0064) 14.6389 (0.0053) 756 (27)
C14 0.1960 (0.0054) )2.8947 (0.0058) 13.6053 (0.0055) 717 (26)
O1 )7.6832 (0.0049) )1.0464 (0.0054) 6.4075 (0.0059) 1208 (22)
O6 4.0867 (0.0051) )1.2391 (0.0070) 15.8755 (0.0067) 1573 (35)
C11 0.8276 (0.0090) )4.1912 (0.0078) 9.0855 (0.0082) 1591 (49)
C15 1.6636 (0.0056) )3.0613 (0.0058) 13.8919 (0.0055) 751 (27)
O5 4.1745 (0.0057) )3.2673 (0.0083) 15.1141 (0.0067) 1756 (37)
C10 0.6738 (0.0061) )2.7537 (0.0069) 8.7846 (0.0059) 810 (30)
C19 3.5909 (0.0078) )2.2182 (0.0120) 15.2534 (0.0074) 1164 (46)
C12 1.7923 (0.0080) )2.2473 (0.0091) 7.8728 (0.0073) 1517 (47)
C20 5.5308 (0.0075) )1.3150 (0.0132) 16.1502 (0.0102) 2452 (79)
DRX instrument (Bruker BiospinCorporation, Billerica,MA,
USA) at 25 C. For Asp-12 1H-NMR: d 8.18 (2H aryl), d 7.92
(2Haryl), d7.5 (1Hamido),d6.92 (1Hamido), d4.65 (1HCH), d
3.67, 3.51 (2H CH2 leucyl side chain), d 2.53, 2.03 (2H CH2-
CH2), d 1.87, 1.69 (4H CH2CH2), d 0.93 (6H terminal methyl
of leucyl side chain); 13C NMR: d 171.97 (amide), d 171.75
(carboxyl), d 164.81 (amide), d 149.12 (aryl), d 139.88 (aryl), d
129.08 (aryl), d 123.38 (aryl), d 52.14 (aliphatic), d 51.33 (ali-
phatic), d 40.47 (aliphatic), d 40.18 (aliphatic), d 39.98 (ali-
phatic), d 39.77 (aliphatic), d 39.56 (aliphatic), d 39.35
(aliphatic), d 38.95 (aliphatic), d 34.9(aliphatic), d
33.62(aliphatic), d24.48 (aliphatic), d22.96 (aliphatic), d 21.49
(aliphatic) and for Asp-20 1H-NMR: d 8.35 (2H aryl), d 8.19
(2H aryl), d 4.54 (1H CH leucyl residue), d 3.67 (3H CH3 ter-
minalmethyl), d 3.34 (2Hpiperidine), d 2.33 (1Hpiperidine), d
1.85 (2H piperidine), d 1.83 (1H CH of leucyl side chain), d
1.79 (1H CH2 of leucyl side chain), d 1.08 (6H CH3 terminal
methyl of leucyl side chain); 13C-NMR: d 177.1 (amido), d 176
(carboxyl), d 168 (amido), d 152.1 (aryl), d 139.8 (aryl), d 128
(aryl), d 123.5 (aryl), d 51.5 (aliphatic), d 50.8 (aliphatic), d 43
(piperidine), d 41.5 (piperidine), d 37.8 (piperidine), d 24.8
(aliphatic), d 22.7 (aliphatic), d 21.3 (aliphatic).
Assessment of inhibition of growth of P. falciparum cultures by
peptides
Experiments requiring Plasmodium cultures used chloroq-
uine-sensitive P. falciparum strain FCK2 (CQ-sensitive;
IC50 18 nm) parasites from Karnataka, India, cultivated in
O+ human erythrocytes in medium supplemented with O+
human serum by the candle jar method of Trager and Jenson
(20). Culture synchrony was maintained by 5% sorbitol
treatment (21), and parasites were observed for viability and
any changes in morphology by standard staining procedures
(Giemsa staining).
Growth inhibition by the peptides of interest was assessed
by monitoring the uptake of [3H] hypoxanthine (22). Syn-
chronized parasites in the early trophozoite stage were cul-
tured in 96-well plates (Nunc, Copenhagen, Denmark) in
Table 3. Hydrogen bonds
N…O distance (A˚) —N–H…O () Symmetry
Intramolecular (Asp-12/Asp-13)
N2…O10 3.046 165.3
N5…O4 3.058 165.7
Intermolecular (Asp-12/Asp-13)
N3…011 3.026 175.5 x + 1 y + 1 z
N6…05 3.103 176.1 x ) 1 y ) 1 z
Intermolecular (Asp-20)
N2…04 2.903 172.0 )x )y )z + 1
Figure 3. Crystal packing in (A) Asp-12 & Asp-13 and (B) Asp-20.
culture medium supplemented with 10% serum at 10%
hematocrit and at an initial parasitemia of at least 3%.
Different concentrations of the peptide in DMSO were ad-
ded such that the final concentration of DMSO did not
exceed 0.05%. Every peptide concentration was tested in
triplicate. [3H] hypoxanthine was added to the culture after
incubation with peptide for 48 h and the cultures were fur-
ther incubated for 31 h. The cultures from the wells of the
plate were harvested using a Nunc cell harvester and inhi-
bition of P. falciparum growth was assessed by measuring
the incorporation of [3H] hypoxanthine using a liquid scin-
tillation counter (Wallac, Global Medical Instrumentation
Inc, Ramsey, MN, USA). The relative percent parasitemia
was plotted vs. log concentration of the inhibitor and the
curve was fit to non-linear regression analysis using
SigmaPlot 2000 software (Systat Software Inc., Point
Richmond, CA, USA). This allowed the calculation of IC50.
Crystallization and data collection details
As Asp-12 was as inhibitory as Asp-13 and Asp-20 and
Asp-21 are likewise equally active, saturated solutions of
the equimolar mixtures of compounds (Asp-12/13 and
Asp-20/21) were prepared in acetone as a solvent and the
crystals were grown by slow evaporation of acetone at
room temperature. Crystals grew in 7 days of crystalliza-
tion setup. The X-ray data were collected on a Bruker AXS
SMART APEX CCD diffractometer, using MoKa radiation
(k ¼ 0.71073 A˚). The structures were determined and re-
fined using SHELXS-97 and SHELXL-97 (23), respectively.
Molecular modeling
As the initial cleavage of Hb is likely to be carried out by
plasmepsin I, the structure of plasmepsin Imodeled based on
the coordinates of plasmepsin II [PDB code:1SME (18)] using
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Figure 5. In vitro growth inhibition assay of the malaria parasite by the
peptides (A) Asp-12 and (B) Asp-20.
Figure 4. Results of molecular docking. (A) Asp-12 in the binding cleft of
plasmepsin I. (B)Details of interactions betweenAsp-12 andplasmepsin I.
the program SYBYL (24) was used as a target for docking
studies. The identity between the two plasmepsins (plas-
mepsins I and plasmepsin II) is 53.1%. The peptides Asp-12,
Asp-13 and Asp-20, Asp-21 were docked into the modeled
plasmepsin I with the program Autodock 3 (25), using the
crystal structure coordinates of the peptides. Autodock 3
creates a grid box around the protein, pre-calculates the en-
ergy values at the grid points, randomly places ligand
(inhibitors) and evaluates successive random changes in the
position, orientation and conformational changes using a
simulatedannealingcoupledwith themetropolis energy test.
Results
Crystal structures
The details of crystal system and diffraction and refinement
parameters of the two compounds are summarized in
Table 1. The structures were determined by direct methods
and the hydrogen atoms were located in difference Fourier
maps. Anisotropic thermal parameters of the non-hydrogen
atoms were refined in the final cycles of the refinement.
Non-hydrogen atoms with their thermal ellipsoids are
shown in Fig. 2.
The coordinates of non-hydrogen atoms with their equiv-
alent isotropic thermal parameters are given in Table 2.
Hydrogenbonds in the crystal structures are given inTable 3.
Asp-12 and Asp-13 crystallize in space group P1 with one
molecule each in the asymmetric unit. Two hydrogen bonds
exist between these twomolecules,made by thenitrogen and
the carbonyl carbon atoms of the leucine residue. In addition,
the molecules are stabilized in the lattice by two additional
intermolecular hydrogen bonds (Table 3, Fig. 3). Asp-20 and
Asp-21 crystallize in space group C2/c with one molecule in
the asymmetric unit. Thus in the crystal Asp-20 and Asp-21
are related by the crystallographic symmetry. These two
molecules are also held by intermolecular hydrogen bonds
made between thenitrogen and the carbonyl oxygen atoms of
the leucine residue (Table 3, Fig. 3).
Docking studies
Molecular docking of these four compounds into modeled
plasmepsin I resulted in negative interaction energy with
efficient binding. Hybrid search (global and adaptive local)
of 50 cycles was carried out for all the four compounds.
We could dock all of them in the binding cleft of plas-
mepsin I. They block the active site by directly interacting
with either one or both of the catalytic aspartates, Asp34
and Asp214 and also with Ser79 situated at the tip of the
flexible flap region. The interaction energies are in the
range of )9 to )8 kcal/mol. The binding modes of one of
them is shown in Fig. 4.
Inhibition of parasite growth
The inhibitory studies indicated no inhibition by Asp-12 &
Asp-13 on P. falciparum cultures up to a concentration of
100 lM, while Asp-20& Asp-21 inhibited the P. falciparum
with an IC50 of 84 lm (Fig. 5).
Discussion
Degradation of Hb by enzymes present in the food
vacuole of the malarial parasite is the key step for
parasite’s survival. Although three different classes of
enzymes are involved in the Hb degradation process,
plasmepsins play a major role in the initial degradation of
Hb. These enzymes can be utilized as targets for drug
development and discovery. There are many peptide like
compounds such as pepstatin and others, which inhibit
plasmepsins effectively, but their inhibitory action is
limited only to plasmepsin enzymes and they do not
show much effect on parasitic growth. This may be due
to their longer chain size because of which they fail to
gain entry into the parasite food vacuole, where Hb deg-
radation takes place.
In our study we have used two compounds which are very
small in size and effectively bind in the active site. The
determination of their crystal structures enabled more
accurate and faster docking calculations. Although docking
studies showed that all the four compounds bind reasonably
well at the active site with favourable energy, in contra-
diction to this, our experimental data showed only Asp-20/
Asp-21 cause inhibition of parasite growth. The contra-
dictory result of docking and experimental studies is due to
the fact that docking is performed directly on the enzyme.
Our experimental and computational results show that
Asp-20/Asp-21 have a better potential to inhibit plasmep-
sins, whereas it is required to modify the design of Asp-12/
Asp-13 to make them more effective as inhibitors of plas-
mepsins.
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